SIGNIFICANT EVENTS AFTER THE BALANCE DATE The following announcements were made via the ASX announcement platform since the end of the reporting period: – On 6 July 2023, the Company announced that it and Promega signed a global joint marketing agreement for INOVIQ’s EXO-NET exosome capture technology and Promega Nucleic Acid purification systems; and – On 9 August 2023, the Company announced results of its Ovarian Cancer Serum equivalence study, showing EXO-NET successfully isolated extracellular vesicles (EVs) from both plasma and serum samples, with variability in results noted for long-term biobanked plasma and serum samples. At the date of this report, other than that outlined above, there have been no matters or circumstances that have arisen since the end of the period which significantly, or may significantly effect: – The Group’s operations in future years; – The results of those operations in future years; or – The Group’s state of affairs in future years. SIGNIFICANT CHANGES IN THE STATE OF AFFAIRS Other than those outlined in this report there were no other significant changes in the state of affairs of the Company during the period. FINANCIAL POSITION The net assets of the Group at 30 June 2023 totalled $19,615,397 (2022: $28,292,837). Total assets at 30 June 2023 totalled $21,508,818 (2022: $30,779,459). The Group had cash and cash equivalents of $7,812,511 at 30 June 2023 (2022: $15,394,847). DIVIDENDS No dividend has been declared, provided for or paid in respect of the year ended 30 June 2023 or 30 June 2022. INDEMNIFICATION AND INSURANCE OF DIRECTORS AND OFFICERS The Company has insurance in place to indemnify directors of the Company against liability incurred to a third party (not being the Company or a related party) that may arise from their position as directors or officers of the Company. In accordance with subsection 300(9) of the Corporations Act 2001, further details have not been disclosed due to confidentiality provisions of the insurance contracts. INDEMNIFICATION OF AUDITORS The Group has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the Group or any related entity against a liability incurred by the auditor. During the financial year, the Group has not paid a premium in respect of a contract to insure the auditor of the Group or any related entity. INTERESTS IN CONTRACTS OR PROPOSED CONTRACTS WITH THE COMPANY During the financial year, no director has had any interest in a contract or proposed contract with the Company being an interest the nature of which has been declared by the director in accordance with Section 300(11)(d) of the Corporations Act 2001 except for the contracts of the executive and non-executive director which are disclosed in the remuneration report. DIRECTORS’ MEETINGS The following table sets out the number of meetings of the Company’s directors held during the year ending 30 June 2023 and the number of meetings attended by each director. Directors’ Meetings Audit Committee Remuneration Committee No. of meetings held while in office Meetings attended No. of meetings held while in office Meetings attended No. of meetings held while in office Meetings attended Dr Geoffrey Cumming 11 11 1 1 1 1 Mr Max Johnston 11 11 3 3 1 1 Mr Philip Powell 11 11 3 3 N/A N/A Professor Allan Cripps 5 4 2 2 1 – Dr Geoffrey Cumming joined the Audit Committee on 23 February 2023 after the resignation of Professor Allan Cripps and was therefore only eligible to attend 1 meeting. Professor Allan Cripps resigned from the IIQ Board on 13 December 2022 and was therefore only eligible to attend 5 Board meetings, 2 Audit Committee meetings and 1 Remuneration committee meeting. Directors’ Report 28 INOVIQ Limited
RkJQdWJsaXNoZXIy MjE2NDg3